Nastech Pharmaceutical Company Announces Initiation of Phase 2
Nastech Pharmaceutical Company Announces Initiation of Phase 2
Forbes - The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled dose ranging study with weight loss as the primary endpoint. The Phase 2 study design will evaluate three different doses of Nastech’s PYY3-36 Nasal
